BRNS vs. CDTX, CYBN, CCCC, GLSI, PRQR, EPRX, NBTX, SCPH, ENTA, and ACTU
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Cidara Therapeutics (CDTX), Cybin (CYBN), C4 Therapeutics (CCCC), Greenwich LifeSciences (GLSI), ProQR Therapeutics (PRQR), Eupraxia Pharmaceuticals (EPRX), Nanobiotix (NBTX), scPharmaceuticals (SCPH), Enanta Pharmaceuticals (ENTA), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.
Barinthus Biotherapeutics vs.
Barinthus Biotherapeutics (NASDAQ:BRNS) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
Cidara Therapeutics has lower revenue, but higher earnings than Barinthus Biotherapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Barinthus Biotherapeutics has a beta of -0.8, meaning that its stock price is 180% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.
25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Barinthus Biotherapeutics has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Barinthus Biotherapeutics' return on equity of -34.26% beat Cidara Therapeutics' return on equity.
Barinthus Biotherapeutics presently has a consensus price target of $5.17, indicating a potential upside of 396.32%. Cidara Therapeutics has a consensus price target of $39.14, indicating a potential upside of 72.47%. Given Barinthus Biotherapeutics' higher probable upside, research analysts plainly believe Barinthus Biotherapeutics is more favorable than Cidara Therapeutics.
In the previous week, Cidara Therapeutics had 20 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 21 mentions for Cidara Therapeutics and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.96 beat Cidara Therapeutics' score of 0.23 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.
Cidara Therapeutics received 440 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 70.43% of users gave Cidara Therapeutics an outperform vote.
Summary
Barinthus Biotherapeutics beats Cidara Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BRNS) was last updated on 3/19/2025 by MarketBeat.com Staff
